(Q64890042)

English

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer a

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer a (English)

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

author name string

Raffit Hassan

1

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Elad Sharon

2

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Jingli Zhang

4

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Alexander Ling

5

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Markku Miettinen

6

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Robert J Kreitman

7

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Seth M Steinberg

8

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Kevin Hollevoet

9

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Ira Pastan

10

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

language of work or name

0 references

publication date

2 July 2014

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

120

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

21

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

3311-3319

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesothelin-family proteins and diagnosis of mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesothelin: a new target for immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localization of mesothelin in epithelial ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mesothelin-targeted agents in clinical trials and in preclinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/24989332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28875

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

1 reference

Europe PubMed Central

30 June 2019

http://europepmc.org/abstract/PMC/6334650

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64890042&oldid=1773515856"